Cargando…
TPGS2000-DOX Prodrug Micelles for Improving Breast Cancer Therapy
BACKGROUND: Doxorubicin (DOX) is an anthracycline antibiotic that inhibits the growth of several solid and hematologic malignant tumors. Increasing the targeting ability of DOX and reducing the multi-drug resistance (MDR) of tumor cells to DOX are major aims for researchers. PURPOSE: In this study,...
Autores principales: | Tang, Lan, Jiang, Wenhui, Wu, Lan, Yu, Xiaolan, He, Zheng, Shan, Weiguang, Fu, Lulu, Zhang, Zhenhai, Zhao, Yunchun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8647655/ https://www.ncbi.nlm.nih.gov/pubmed/34880613 http://dx.doi.org/10.2147/IJN.S335405 |
Ejemplares similares
-
Exploration of the inhibition action of TPGS on tumor cells and its combined use with chemotherapy drugs
por: Tang, Lan, et al.
Publicado: (2023) -
TPGS/Phospholipids Mixed Micelles for Delivery of Icariside II to Multidrug-Resistant Breast Cancer
por: Song, Jie, et al.
Publicado: (2015) -
Combined administration of PTX and S-HM-3 in TPGS/Solutol micelle system for oncotarget therapy
por: Li, Weiguang, et al.
Publicado: (2019) -
Poloxamer 407/TPGS mixed micelles for delivery of gambogic acid to breast and multidrug-resistant cancer
por: Saxena, Vipin, et al.
Publicado: (2012) -
Nano‐gold micelles loaded Dox and Elacridar for reversing drug resistance of breast cancer
por: Wen, Liu‐Jing, et al.
Publicado: (2022)